Efficacy and safety are equivalent to the original drug (Johnson & Johnson/Merck & Co.
Adalimumab(Ahrasin) is a fully human anti-tumor necrosis factor-α(TNF-α) monoclonal antibaby, a biosimilar drug of HUMIRA. Excessive inflammation in a variety of immune-mediated diseases in humans are associated with TNF-α.
Indications
Rheumatoid Arthritis.
Crohn's Disease.
Juvenile idiopathic arthritis.
Paediatric plaque psoriasis.
Ankylosing spondylitis.
Uveitis.
Psoriasis.
Paediatric Crohn’s disease.
Strength
0.8ml: 40mg
Recommended reading:
Adalimumab Biosimilar: A Promising Alternative to Expensive Biologics
Adalimumab Biosimilars: Advancing Healthcare Access with Kexing Biopharm
Download instructions
Contact us